Sanofi, Novo, Lilly Look To Ditch Minn. AG's Insulin Suit

Law360 (August 13, 2019, 6:28 PM EDT) -- Sanofi-Aventis U.S. LLC, Novo Nordisk Inc. and Eli Lilly and Co. urged a New Jersey federal judge Monday to toss the Minnesota attorney general’s insulin pricing lawsuit against them, arguing that the racketeering allegations of deceptive prices are undone by Minnesota law and the state’s own practices.

The drugmakers argued in a joint dismissal brief that the Racketeer Influenced and Corrupt Organization Act, state consumer protection and unjust enrichment claims all must be tossed from the litigation, which is only one of the lawsuits to spring from ballooning insulin costs. The claims fail for a variety of reasons, according to the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS